In a 67‑year‑old female with hypertension, arthritis and gout treated with losartan, amlodipine, colchicine and etoricoxib (Arcoxia), who presents with melena, progressive weakness, light‑headedness, epigastric pain, constipation and mild abdominal distension, what is the probable working impression and the differential diagnosis?

Probable Working Impression and Differential Diagnosis

The probable working impression is NSAID-induced peptic ulcer disease with acute upper gastrointestinal bleeding (melena), complicated by severe anemia and possible drug-induced myopathy from colchicine in the setting of chronic kidney disease. 1

Primary Working Diagnosis

NSAID-Induced Peptic Ulcer Disease with Upper GI Bleeding

This 67-year-old woman's presentation of melena, progressive weakness, lightheadedness, epigastric pain, and pale conjunctivae strongly indicates peptic ulcer disease as the bleeding source. 1

• Peptic ulcer disease accounts for 35–50% of all upper GI bleeding cases, making it the single most common etiology 1
• Her chronic use of etoricoxib (Arcoxia), a COX-2 inhibitor NSAID for arthritis and gout, is a major risk factor for PUD-related bleeding 1
• The combination of epigastric pain with melena is highly characteristic of gastroduodenal ulceration 2
• Pale palpebral conjunctivae on examination indicates significant anemia from blood loss 3
• Her hemodynamic symptoms (lightheadedness, progressive weakness, inability to stand) suggest substantial blood loss requiring urgent evaluation 3

Severe Anemia Secondary to GI Blood Loss

• The constellation of melena, progressive generalized weakness, lightheadedness, and pale conjunctivae indicates acute anemia from gastrointestinal hemorrhage 3
• Hemoglobin level of 70 g/L or less warrants blood transfusion per consensus guidelines 3
• The transient speech difficulty ("blanking out") while maintaining awareness may represent cerebral hypoperfusion from severe anemia rather than a primary neurologic event 3

Drug-Induced Myopathy (Colchicine Toxicity)

The reported "quadriplegia" and progressive inability to stand or feed herself raises concern for colchicine-induced myotoxicity, particularly given her renal impairment from hypertension. 4

• Colchicine myotoxicity presents with proximal muscle weakness, generalized weakness, and inability to ambulate, typically occurring days to weeks after initiation in patients with renal impairment 4
• Renal insufficiency is the primary risk factor for colchicine-induced myotoxicity, as colchicine clearance is reduced by 55–85% in patients with mild to moderate renal impairment 5
• Her hypertension treated with losartan and amlodipine suggests underlying chronic kidney disease, which impairs colchicine elimination 5
• The poor recall and inability to establish baseline functional status is consistent with the patient's confusion about symptom onset 4

Differential Diagnoses (in order of likelihood)

1. Gastric or Duodenal Ulcer (Most Likely)

• Duodenal ulcers are the single most frequent source of UGIB, followed by gastric ulcers 1
• NSAID use (etoricoxib) is a major risk factor for ulcer formation and bleeding 1
• The epigastric pain localizes the pathology to the gastroduodenal region 2

2. Gastroduodenal Erosions

• Gastroduodenal erosions cause 8–15% of UGIB and are frequently associated with NSAID use 1
• These may present similarly to ulcers but are typically more superficial 1

3. Dieulafoy Lesion

• Dieulafoy lesion accounts for 1–2% of acute UGIB but is under-recognized and can cause massive bleeding 1
• It involves a tortuous submucosal artery that erodes into the gastric lumen, often on the posterior gastric wall 1
• Should be considered when bleeding is severe and out of proportion to visible mucosal abnormalities 1

4. Esophageal Pathology (Less Likely)

• Esophageal sources contribute 5–15% of UGIB, including esophagitis, esophageal ulcers, and Mallory-Weiss tears 1
• The absence of hematemesis and presence of epigastric pain make esophageal sources less likely 2

5. Gastric Malignancy (Consider)

• Upper GI malignancies can present with bleeding, particularly in elderly patients 1
• The chronic nature of symptoms and age warrant consideration, though acute presentation is less typical 1

6. Angiodysplasia or Vascular Malformations (Less Likely)

• These are recognized causes of UGIB but typically present with chronic, intermittent bleeding rather than acute melena 1

7. Aortoenteric Fistula (Rare but Catastrophic)

• Aortoenteric fistula is a rare cause of potentially catastrophic GI hemorrhage 2
• Should be considered in patients with prior aortic surgery or grafts, which this patient denies 2
• The absence of surgical history makes this diagnosis unlikely 2

Critical Risk Stratification

This patient has multiple high-risk features for rebleeding and mortality that mandate urgent intervention: 3

• Age > 65 years (she is 67) 3
• Hemodynamic instability (lightheadedness, inability to stand, progressive weakness) 3
• Melena (black stool) 3
• Pale conjunctivae indicating significant anemia 3
• Hypertension (BP 140/90 mmHg on admission) 3
• Multiple comorbidities (hypertension, arthritis, gout, possible chronic kidney disease) 3

Prognostic scales such as the Glasgow-Blatchford and Rockall scores should be calculated to stratify risk. 3

Immediate Diagnostic and Management Algorithm

Step 1: Aggressive Resuscitation and Risk Assessment

• Initiate aggressive IV fluid resuscitation and obtain immediate hemoglobin level 3
• Transfuse packed red blood cells if hemoglobin ≤ 70 g/L 3
• Calculate Glasgow-Blatchford and pre-endoscopic Rockall scores to identify need for urgent intervention 3
• Obtain complete blood count, coagulation studies, renal function (creatinine, BUN), liver enzymes, and creatine kinase 3, 4

Step 2: Early Upper Endoscopy (Within 24 Hours)

• Upper endoscopy is the diagnostic gold standard and identifies the bleeding source in approximately 95% of cases 1
• Emergency endoscopy is indicated for patients with persistent hemorrhage, vital sign abnormalities, or repeated transfusion requirements 1
• Endoscopy allows for therapeutic intervention (e.g., thermal coagulation, injection therapy, clip placement) 1

Step 3: Discontinue Offending Medications

• Immediately discontinue etoricoxib (Arcoxia) due to its role in NSAID-induced ulcer bleeding 1
• Discontinue or dose-adjust colchicine given concern for myotoxicity in the setting of renal impairment 4
• Continue losartan and amlodipine for blood pressure control, as these are not implicated in her acute presentation 6

Step 4: Evaluate for Colchicine Myopathy

• Obtain creatine kinase (CK), ALT, and AST levels to assess for myotoxicity 4
• Perform electromyography (EMG) if CK is elevated to confirm colchicine-induced myopathy 4
• Assess renal function (creatinine clearance) to determine degree of colchicine accumulation 5
• Expect symptom resolution within 1 week after colchicine discontinuation if myopathy is present 4

Step 5: Initiate Proton Pump Inhibitor Therapy

• Start high-dose intravenous proton pump inhibitor (PPI) to reduce rebleeding risk in peptic ulcer disease 3
• Continue PPI therapy after endoscopic confirmation of ulcer 3

Step 6: Address Underlying Gout Management

• Avoid NSAIDs and colchicine for acute gout in this patient due to contraindications (GI bleeding, renal impairment, prior myotoxicity) 7, 8
• Consider systemic corticosteroids for future gout flares, as they are equally effective to NSAIDs and safer in patients with multiple comorbidities 8, 9
• Intra-articular corticosteroids are an alternative for monoarticular gout 7

Common Pitfalls and Caveats

Pitfall 1: Attributing Weakness to Neurologic Event Rather Than Anemia or Myopathy

• The transient speech difficulty and progressive weakness may be misinterpreted as stroke, but the absence of focal neurologic deficits, maintenance of awareness, and resolution without intervention suggest cerebral hypoperfusion from anemia rather than cerebrovascular accident 3
• Do not overlook drug-induced myopathy as a cause of "quadriplegia" in patients on colchicine with renal impairment 4

Pitfall 2: Underestimating Bleeding Severity Due to Absence of Hematemesis

• Melena alone can indicate significant upper GI bleeding; hematemesis is not required for diagnosis 2
• Pale conjunctivae and hemodynamic symptoms are critical indicators of severe anemia requiring urgent intervention 3

Pitfall 3: Continuing NSAID Therapy in High-Risk Patients

• Etoricoxib (Arcoxia) is a COX-2 inhibitor NSAID that carries significant GI bleeding risk, particularly in elderly patients with comorbidities 10, 11
• COX-2 inhibitors are NOT gastroprotective and increase bleeding risk similarly to non-selective NSAIDs 8

Pitfall 4: Failing to Dose-Adjust Colchicine in Renal Impairment

• Colchicine clearance is reduced by 55–85% in renal impairment, leading to accumulation and myotoxicity 5
• Renal impairment is the primary risk factor for colchicine-induced myopathy 4
• Colchicine should be avoided or used at extremely low doses (50–100 mg on alternate days) in elderly patients with renal dysfunction 7

Pitfall 5: Missing Rare but Life-Threatening Causes

• Maintain high suspicion for Dieulafoy lesion if bleeding is severe and endoscopy shows minimal mucosal abnormality 1
• Consider aortoenteric fistula in any patient with prior aortic surgery, though this patient has no such history 2